How long GLP-1 side effects last: what the labels report

What the US labels say about timing

None of the US prescribing information sets a number of days. What each one does say is when stomach side effects were most frequent, and how many people stopped treatment because of them. The table puts the two side by side. Each label describes its own trials, so the figures cannot be compared directly from one medicine to another.

Durations measured in European product information

The European Medicines Agency documents sometimes go further than the US labels and describe how long individual episodes lasted, or how the rate changed week by week. These are trial summaries, not predictions for one person.

• A median is the middle value: half of the episodes were shorter and half longer. Someone can have several separate episodes, for example after each dose step.

What the trial analyses add

A pooled analysis of the STEP 1, 2 and 3 trials of semaglutide 2.4 mg, with 2,117 people on the medicine and 1,262 on placebo over 68 weeks, found that 98.1% of stomach events were mild to moderate and most were transient, occurring most often during or shortly after dose escalation; 4.3% stopped permanently because of them ^[10]. The analysis was funded by the manufacturer, and the published abstract does not break the timing down week by week.

In the same paper, data from STEP 4 looked at people who had already tolerated a 20-week run-in. Staying on semaglutide was described as well tolerated ^[10], although the STEP 4 report still found stomach events in 49.1% of those who continued, against 26.1% of those switched to placebo, over the following 48 weeks ^[12]. In other words, symptoms became less of a problem for most people but did not vanish for everyone.

For tirzepatide, the 3-year SURMOUNT-1 report in adults with obesity and prediabetes found that stomach events were mostly mild to moderate and occurred primarily during dose escalation in the first 20 weeks, with no new safety signals over the longer period ^[11].

Why each dose step can restart the clock

• Supported by the labels: every label ties stomach side effects to the escalation phase, and the dosing sections say the step-up schedule is there to reduce that risk ^[1][2][3].
• Supported by the labels: the tirzepatide and orforglipron labels say the slowing of stomach emptying is largest after the first dose and becomes smaller over time ^[2][6].
• Proposed but not measured: it is tempting to link these two facts, so that symptoms fade as the stomach effect settles. The labels report both findings but do not show that one explains the other.
• General background: after a longer break, the Wegovy® and Foundayo™ labels tell prescribers to restart the step-up at a lower dose, again to lower the risk of stomach side effects ^[1][6]. When and how that happens is your prescriber’s decision.

Effects that run on a slower clock

• Constipation: in the Wegovy® trials it lasted much longer per episode than nausea, a median of 47 days, although it was mostly mild to moderate ^[7].
• Altered skin sensations (dysesthesia) on Wegovy® 7.2 mg: reported by 22% against 6% on 2.4 mg and 0.3% on placebo. Most people recovered after the dose was paused, lowered or stopped, but 18% had not recovered by the end of the trial, and 17 of 38 people moved back up to 7.2 mg had it again ^[1].
• Hair loss: the labels link it to weight reduction rather than to the start of treatment, so it is often noticed months in. The European Wegovy® information says it was mostly mild and most people recovered while staying on treatment ^[1][7].
• Heart rate: in the European Saxenda® information, the rise in pulse peaked after about 6 weeks and reversed after liraglutide was stopped ^[9]. It has its own article on this site.
• Gallbladder problems, pancreatitis and the other section 5 warnings: the labels do not tie them to the first weeks of treatment, so a later onset does not rule them out ^[1][2].

After the last dose

The labels do not say how long side effects continue after stopping, but they do say how long the medicine stays. Semaglutide has a half-life of about one week, and according to the Wegovy® label it can still be found in the blood 5 to 7 weeks after the final dose ^[1]. Tirzepatide’s half-life is about 5 days, orforglipron’s 29 to 49 hours and liraglutide’s about 13 hours ^[2][5][6].

The overdose sections make a related point: because of these half-lives, a longer period of observation may be needed after too much medicine ^[1][2]. That concerns overdose, not ordinary side effects, but it explains why a weekly injection does not stop acting the day a dose is skipped.

When the cause may be something else

A symptom that keeps going is not always the medicine. MedlinePlus lists stomach infections, food poisoning, reflux, migraine, pregnancy, motion sickness and other medicines among common causes of nausea, and appendicitis, a blocked bowel and ulcers among the more serious ones ^[14]. For diarrhea it names viral gastroenteritis as the most common cause, along with some antibiotics, magnesium laxatives, lactose intolerance, celiac disease and inflammatory bowel disease ^[15].

The labels add two warnings that can look like ordinary stomach upset at first: pancreatitis, with severe stomach pain that may spread to the back, and gallbladder disease, with upper stomach pain, fever, yellow skin or eyes, or clay-coloured stools ^[1]. A change in the kind of symptom matters as much as how long it lasts.

What may help while it settles

The Medication Guides say drinking fluids lowers the chance of dehydration when stomach side effects strike ^[1]. Novo Nordisk’s Wegovy® page describes nausea as generally transient and suggests asking your clinician about eating more slowly, choosing foods that contain water and getting fresh air, and about smaller, more frequent meals, stopping when full, avoiding greasy or spicy food and not lying down after eating ^[13].

MedlinePlus explains that with diarrhea, the main tasks at home are drinking enough to avoid dehydration and knowing which danger signs to watch for ^[15]. Medicines for nausea or diarrhea, including over-the-counter ones, are a question for your prescriber or pharmacist; the GLP-1 labels do not name a remedy.

Ozempic®, Wegovy® and Saxenda® are registered trademarks of Novo Nordisk A/S. Mounjaro®, Zepbound® and Trulicity® are registered trademarks of Eli Lilly and Company, and Foundayo™ is a trademark of Eli Lilly and Company. PepLabo is not affiliated with or endorsed by Novo Nordisk or Eli Lilly and Company.